LEADER 02294cam a2200517 a 4500001    9975890213506421
005    20231120111052.0
006    m     o  d f
007    cr b||||||||||
008    130429s1979    mdua    ob   f000 0 eng c
027    CAS no. 128-37-0
035    ocn841174758
035    (NjP)7589021-princetondb
035     |z(NjP)Voyager7589021
040    GPO |beng |cGPO |dGPO |dMvI
042    pcc
049    DOCS
074    0507-G-12 (online)
086 0  HE 20.3159/2:150
088    NCI-CG-TR-150
090    Electronic Resource
245 00 Bioassay of butylated hydroxytoluene (BHT) for possible carcinogenicity / |cCarcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health.
264  1 Bethesda, Md. : |bU.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, |c1979.
300    1 online resource (ix, 114 pages) : |billustrations.
336    text |btxt |2rdacontent
337    computer |bc |2rdamedia
338    online resource |bcr |2rdacarrier
490 1  Carcinogenesis technical report series ; |vno. 150
490 1  DHEW publication ; |vno. (NIH) 79-1706
500    This bioassay of butylated hydroxytoluene (BHT) was conducted at the NCI Frederick Cancer Research Center (FCRC), operated for NCI by Litton Bionetics. Inc.
500    Includes bibliographical references (p. 43-45).
500    "CAS no. 128-37-0."
500    "NCI-CG-TR-150."
650  0 Carcinogens.
650  0 Antioxidants |xToxicology.
650  0 Food preservatives |xToxicology.
710 2  Frederick Cancer Research Center.
710 2  Litton-Bionetics, inc.
710 2  Carcinogenesis Testing Program (U.S.)
710 2  National Institutes of Health (U.S.)
710 2  National Cancer Institute (U.S.). |bDivision of Cancer Cause and Prevention.
776 08  |iPrint version: |tBioassay of butylated hydroxytoluene (BHT) for possible carcinogenicity |w(OCoLC)5105912
830  0 DHEW publication ; |vno. (NIH) 79-1706.
830  0 National Cancer Institute carcinogenesis technical report series ; |vno. 150.
945    DOCS |cHE 20.3159/2:150
956 40  |uhttps://purl.fdlp.gov/GPO/gpo36348